Business Context and Reporting Period
Company: NanoVibronix, Inc. (Note: Metadata listed "Envue Medical, Inc." but the filing text identifies the registrant as NanoVibronix, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: July 31, 2019
Reporting Period: Specific event date of July 31, 2019.
Business Context: The Company, a Delaware corporation, entered into material definitive agreements to raise capital through private placements of Series E Convertible Preferred Stock and Common Stock.
Key Financial Metrics
- Aggregate Gross Proceeds: $1,000,000 raised from the initial closings of the Preferred Financing and Common Financing.
- Stockholders' Equity: Following the financing, the Company reported more than $2,500,000 in stockholders' equity.
- Offering Price: $2.00 per unit for both the Preferred Stock/Warrant units and Common Stock/Warrant units.
- Warrant Exercise Price: $2.50 per share for both Preferred Warrants and Common Warrants.
- Revenue, Profit, Cash Flow, Margins, Debt: The filing text does not provide specific values for revenue, net income, operating cash flow, margins, or outstanding debt levels.
Material Changes Versus Prior Period
This filing reports a discrete capital event rather than a comparative period financial statement. The material change is the increase in capitalization and the issuance of new securities:
- Capital Structure: Issuance of Series E Convertible Preferred Stock and Common Stock to accredited investors.
- Liquidity: Immediate infusion of $1,000,000 in gross proceeds.
- Equity Status: The financing was structured to ensure the Company maintained stockholders' equity above $2,500,000, likely to meet Nasdaq Capital Market listing requirements.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Agreements
- Stockholder Approval: Conversion of Series E Preferred Stock to Common Stock and voting rights are contingent upon stockholder approval. The Company agreed to hold a special stockholder meeting within 90 days of the closing date.
- Registration Obligations: The Company must file a registration statement for the resale of shares within 60 days of stockholder approval and have it declared effective within 120 to 150 days.
- Liquidated Damages: If registration deadlines are missed, the Company must pay investors 1.0% of the purchase price per month, capped at 5% of the aggregate purchase price.
- Warrant Terms: Preferred Warrants are exercisable immediately for 7 years. Common Warrants have a 6-month vesting period before becoming exercisable for 7 years.
Risks and Contingencies
- Beneficial Ownership Limitation: Holders of Series E Preferred Stock cannot convert if it would result in beneficial ownership exceeding 9.99% of outstanding Common Stock.
- Conversion Restrictions: Until stockholder approval is obtained, Series E Preferred Stock is not convertible and holders have no voting rights.
- Regulatory Compliance: Failure to meet SEC registration timelines triggers cash penalties.
Important Facts for Investor Verification
- Verify the exact split of the $1,000,000 proceeds between the Preferred Financing and Common Financing.
- Confirm the date of the special stockholder meeting required to approve the conversion of Series E Preferred Stock.
- Monitor the filing status of the registration statement for the resale of shares to ensure compliance with the 60-day filing and 120/150-day effectiveness deadlines.
- Review the full text of the Amended and Restated Certificate of Designation (Exhibit 4.1) for detailed rights and preferences of the Series E Preferred Stock.
- Check subsequent filings to confirm if the Company has met the Nasdaq listing requirements regarding stockholders' equity.